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Background: The purpose of this study was to investigate whether long-term
inflammation is related to the incidence of dementia in a prospective observational study.
Methods: In total, 732 Korean community-dwelling elderly people >65 years were
evaluated at baseline. Of the 625 without dementia, 518 (83%) were followed over a
2.4-years period, and the incidence of dementia was determined. Cytokine [interleukin
(IL)-1α, IL-1β, IL-6, IL-8, and tumor necrosis factor (TNF)-α] levels were measured
at baseline and follow-up. The individual and combined effects of cytokine levels
on dementia were evaluated after adjusting for potential covariates (lifestyle factors,
demographics, disability, cognitive function, and presence of the APOE e4 allele) and
a Bonferroni correction.
Results: Incident dementia was associated with increased serum cytokine levels after 2
years; the association remained significant for TNF-α, IL1-α, and IL-1β concentrations
even after applying a Bonferroni correction. The analysis of the combined effects of
the five cytokines showed independent associations between increases in the summed
number of higher cytokine levels, between baseline and follow-up. However, incident
dementia was not expected based on higher baseline pro-inflammatory cytokine levels.
Conclusion: Our results suggest that dementia may precede changes in serum cytokine
levels and inflammatory processes, rather than resulting from elevated pro-inflammatory
cytokines.
Keywords: cytokines, dementia, geriatric psychiatry, inflammation, longitudinal studies
INTRODUCTION
Dementia is a group of symptoms involving impairments in attention, memory, language, executive
function, perception, and social cognition (1). As dementia has a high prevalence and a progressive,
irreversible course in older adults (2, 3), it has become a global challenge for public health (4, 5).
Understanding the etiology of dementia is essential for early diagnosis and treatment. Dementia has
complex and heterogeneous etiologies, including amyloid plaques, tau-pathy, and cerebrovascular
disease (6–8). Recently, the inflammatory process has received attention in the pathogenesis of
dementia (9, 10).
Cytokines play a pivotal role in regulating the inflammatory response. The involvement of
cytokines in dementia is supported by studies (11–13) showing that the levels of pro-inflammatory
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cytokines [e.g., tumor necrosis factor alpha (TNF-α), interleukin
(IL)-1α, IL-1β, IL-6, and IL-8] are altered. A recent meta-analysis
study reported significantly higher levels of the proinflammatory
cytokines TNF-α, IL-6, IL-1β, IL-2, and IL-18 in peripheral blood
samples of patients with Alzheimer’s disease (AD) compared with
a control group (14). However, causal relationships cannot be
confirmed from case-control and cross-sectional investigations
because increases in pro-inflammatory processes could be caused
by disease pathophysiology (15, 16). Therefore, longitudinal
studies are needed for clarification, although such studies have
been scarce and have reported inconsistent findings. Some
previous longitudinal studies have reported that the incidence
of dementia is associated with TNF-α, IL-6, and C-reactive
protein (CRP) concentrations (10, 17, 18), whereas other studies
have found no relationship between baseline inflammation and
future risk of dementia after adjusting for confounding factors
(19, 20). These studies of inflammation-related dementia risk
were conducted at a single time point, providing only the
temporality of disease progression. Therefore, whether increased
cytokine levels at a baseline evaluation can predict dementia risk
remains unknown. To address these limitations, we analyzed
data from a 2.4-years longitudinal cohort study to investigate
prospectively the associations between five serum cytokine levels
estimated at baseline and at follow-up with the incidence of
dementia.
METHODS
Study Overview and Participants
This prospective cohort study was carried out from 2001 to
2003 in Kwangju, South Korea. Details of the study design
have been described previously (21). Briefly, 732 community
dwelling subjects aged >65 years from Kwangju, South Korea,
were recruited from national resident registration lists. Of the
732 participants, 625 did not receive a dementia diagnosis at
the baseline evaluation. Among these, 518 (83%) finished all
assessments at follow-up. A secondary analysis was carried
out with these 518 participants. The study was performed in
accordance with the Declaration of Helsinki. Written informed
consent was obtained for the study, and this study was approved
by the Chonnam National University Hospital Institutional
Review Board.
Baseline Sampling and Assessments
Examinations included a fully structured diagnostic interview for
AD and vascular dementia, peripheral blood sampling for five
serum pro-inflammatory cytokines, and a formal evaluation of
covariate factors.
Dementia Evaluation
Dementia assessments were performed at the baseline and
follow-up. Examinations included the Mini-Mental State
Examination (MMSE) (22), the Instrumental Activities of Daily
Living Scale (23), the Clinical Dementia Rating scale (24),
history, and a neurological examination. Clinical researchers
assigned consensus diagnoses using standard criteria for
dementia (1), AD (25), and vascular dementia (26). If AD
and vascular dementia pathologies were mixed, they were
diagnosed as either, using the criteria. In this study, we divided
the participants into two different groups of incident dementia
and no incident dementia.
Biochemical Analyses
Blood samples were collected from the participants in a fasting
state and were taken in the morning when possible. The blood
samples were collected in EDTA tubes, centrifuged, separated
into plasma aliquots, and frozen at −70◦C within 2 h of
collection. Biochemical assays were conducted for five serum
cytokines: IL-1α, IL-1β, IL-6, IL-8, and TNF-α. Serum cytokine
levels were analyzed using a solid-phase sandwich enzyme-linked
immunosorbent assay (ELISA) kit (Invitrogen, Camarillo, CA,
USA) according to the manufacturer’s instructions. To reduce
assay variation, all specimens were analyzed on the same day,
in duplicate, in random order, by a technician blinded to the
participant’s status. The inter-assay coefficients of variation were
4–8% for IL-1α, 5–9% for IL-1β, 6–9% for IL-6, 3–6% for IL-8,
and 5–7% for TNF-α. The intra-assay coefficients of variation
were 4–6% for IL-1α, 4–7% for IL-1β, 4–5% for IL-6, 2–4% for
IL-8, and 3–6% for TNF-α.
Covariates
Several potential factors that may be associated with serum
cytokine levels were investigated based on previous studies (6–
8). Age, gender, and education were recorded. Depression was
evaluated by the community version of the Geriatric Mental
State schedule (GMS) (27). Functional disability wasmeasured by
the Korean version of the World Health Organization Disability
Assessment Schedule II (WHODAS II) (28). Smoking status
was investigated and participants were categorized into current
smokers or not current (ex- and never) smokers. History of
alcohol use was ascertained from the participants, and verified
by family members. Low risk alcohol drinking was defined,
based on consuming more than 14 drinks per week during the
previous 3 months for men or more than 7 drinks per week
for women, following the guidelines from the National Institute
of Alcohol Abuse and Alcoholism (29). Physical activity was
checked at baseline by asking about work and leisure activities
on a 4-point scale (not at all active, not very active, fairly
active, and very active) according to the standard protocol (30).
A summary vascular risk score was calculated by summing
self-reported disorders (stroke, heart disease, hypertension, and
diabetes), hypercholesterolemia (fasting cholesterol>200mg/dl),
and obesity (body mass index >25 kg/m2). The apolipoprotein E
(APOE) genotype was reflected as a covariate in analyses of the
relationship with AD.
Follow-Up Assessments
The follow-up was carried out in 2003 (31). Attempts were
made to follow up 2 years after the baseline appointment
(mean interval [standard deviation (SD)], 2.4 (0.3) years).
Blood samples were collected to determine five serum pro-
inflammatory cytokines, centrifuged within the hour, and stored
at −70◦C. The same biomedical assays were carried out
using the ELISA method described above. Clinical researchers
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FIGURE 1 | Flow chart of the study.
assigned consensus diagnoses using standard criteria (1, 25,
26).
Statistical Analysis
The study design is outlined in Figure 1. Associations between
baseline characteristics, demographics, assessment scales
(MMSE, WHODAS II, and GMS depression) (27, 28, 32),
smoking, alcohol, physical activity, and vascular risk score
with incident dementia were analyzed using t- or χ2-tests as
appropriate. Results with significant associations (p-value< 0.05)
were reflected in subsequent multivariate analyses. Unadjusted
associations between the incidence of dementia and baseline
serum cytokine concentrations and changes (from baseline to
follow-up) were investigated using the Mann–Whitney U-test.
The baseline levels and changes in levels were recorded as
binary values of “lower” or “higher” (i.e., below or above the
median value). Odds ratios and 95% confidence intervals were
calculated for the associations between the baseline cytokine
values and increases in cytokine levels during the follow-up in
subjects with dementia. These associations were analyzed before
and after adjusting for significant baseline covariates using
logistic regression models. Because cytokines have demonstrated
additive and synergistic effects on AD (21), the combined effects
of the pro-inflammatory cytokines were calculated by summing
the number of cytokines with higher levels at baseline and the
number of cytokines with higher levels at the follow-up, and then
assigning ordinal values (0, 1, 2, 3, 4, 5) to each. Associations
between baseline values and the summed number of higher
cytokine levels with the incidence of dementia were assessed
initially by the χ2-test for a linear trend (i.e., 1 df), and then with
the same logistic regression models to adjust for covariates. The
Bonferroni correction was applied to maintain an overall type I
error rate of 0.05 against the multiple comparisons. All statistical
analyses were performed with SPSS software (ver. 21.0; SPSS
Inc., Chicago, IL, USA).
RESULTS
Participant Characteristics
The recruitment procedure for the baseline and follow-up aspects
of the study and distribution of dementia diagnoses are shown
in Figure 1. Among the 625 subjects without dementia at the
baseline evaluation, 518 (83%) completed all evaluations. At
follow-up, incident dementia [mean interval (SD), 2.4 (0.3)
years] was diagnosed in 45 participants (8.7%): 34 (6.6%) had
AD, seven (1.4%) had vascular dementia, and four had “other”
dementia (0.8%). Median [interquartile range (IQR)] IL-1α, IL-
1β, IL-6, IL-8, and TNF-α levels were 40.3 (32.3–48.3), 12.0
(11.1–12.9), 9.5 (8.9–10.5), 20.1 (18.7–23.1), and 40.7 (37.5–
43.9) pg/ml, respectively. Baseline characteristics are compared
by the dementia diagnosis in Supplementary Table 1. Incident
dementia was associated with older age, lower education, lower
MMSE score, higher WHODAS II score, lower physical activity,
and presence of the APOE e4 allele. The median (IQR) changes
from baseline to follow-up for IL-1α, IL-1β, IL-6, IL-8, and
TNF-α levels were +0.3 (0.3–1.9), +0.6 (0.4–0.8), +0.6 (0.6–
4.0), +0.3 (0.1–1.8), and +1.2 (1.0–3.9), pg/ml, respectively.
Baseline levels of and follow-up changes in serum cytokine
concentrations according to the dementia diagnosis are shown
in Supplementary Table 2.
Baseline and Follow-Up Concentrations of
Serum Cytokines by Dementia Incidence
Unadjusted associations between serial serum cytokine levels
and incident dementia are summarized in Table 1. Incident
dementia was associated with increases in all five serum
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TABLE 1 | Baseline levels of and follow-up changes in serum cytokine
concentrations by incident dementia status.
No incident
dementia
(N = 473)
Incident
dementia
(N = 45)
P-value*
BASELINE VALUES
Tumor necrosis factor-α 40.3 (32.5–48.5) 40.7 (31.7–50.4) 0.921
Interleukin-1α 12.1 (11.1–12.9) 11.9 (11.2–14.1) 0.505
Interleukin-1β 9.5 (8.9–10.5) 9.3 (8.8–10.5) 0.981
Interleukin-6 20.0 (18.0–22.3) 21.0 (17.7–25.0) 0.146
Interleukin-8 40.4 (37.3–43.5) 43.0 (40.5–50.3) <0.001
FOLLOW-UP VALUES
Tumor necrosis factor-α 42.1 (36.5–47.7) 42.1 (37.1–47.1) 0.469
Interleukin-1α 13.2 (12.2–14.2) 13.9 (13.2–14.6) 0.001
Interleukin-1β 10.1 (9.5–11.1) 11.2 (10.0–12.6) <0.001
Interleukin-6 22.1 (19.5–24.7) 24.6 (22.6–28.1) <0.001
Interleukin-8 41.1 (38.4–44.6) 45.0 (38.5–53.5) 0.002
CHANGED VALUES
Tumor necrosis factor-α +1.2 (1.0–1.4) +4.5 (−0.3–6.0) 0.002
Interleukin-1α +0.3 (0.3–1.9) +1.8 (1.1–2.0) 0.001
Interleukin-1β +0.6 (0.6–0.7) +2.2 (0.0–2.6) <0.001
Interleukin-6 +0.6 (0.6–3.3) +4.8 (0.8–6.0) 0.005
Interleukin-8 +0.3 (0.0–0.6) +3.6 (−3.9–7.6) 0.100
*Mann Whitney test, Bold character denotes statistical significance after Bonferroni
correction.
Data are median (IQR).
cytokines during the follow-up, and the strength of the
significance remained for TNF-α, IL1-α, and IL-1β after
applying the Bonferroni correction. Incident dementia was
associated with a higher IL-8 level at baseline, and the strength
of the significance remained after applying the Bonferroni
correction. The same analyses were repeated by dementia
diagnosis and are presented in Supplementary Table 2.
Incident AD was significantly associated with increases
in IL1-α, IL-1β, and IL-6 levels but not with baseline
cytokine levels after applying Bonferroni corrections.
Incident vascular dementia was not associated any cytokine
value.
Binary Higher Baseline Levels and
Increasing Follow-up Level Categories of
Serum Cytokines by Incident Dementia
Status
The logistic regression results show a positive relationship
between baseline and follow-up cytokine levels with the
incidence of dementia (Table 2). Incident dementia was
associated with IL-8 levels at baseline in unadjusted analyses.
However, the association was not significant after adjusting for
covariates. Incident dementia was significantly associated with
higher levels of all five cytokines before and after adjustment,
even after applying the Bonferroni correction. Incident
dementia was not associated with higher pro-inflammatory
cytokine level category at baseline before or after adjusting for
covariates.
TABLE 2 | Associations of incident dementia with (binary) higher baseline cytokine
levels and (binary) more pronounced increase in levels over follow-up.
Unadjusted Adjusteda
BASELINE HIGHER LEVELS
Tumor necrosis factor-α 1.05 (0.57–1.93) 0.83 (0.43–1.60)
Interleukin-1α 0.97 (0.47–1.59) 1.29 (0.65–2.56)
Interleukin-1β 0.78 (0.42–1.45) 1.09 (0.56–2.14)
Interleukin-6 1.16 (0.63–2.14) 1.22 (0.63–2.36)
Interleukin-8 2.67 (1.37–5.21)† 2.56 (1.25–5.23)*
MORE PRONOUNCED INCREASE IN LEVELS
Tumor necrosis factor-α 7.83 (3.92–15.63)‡ 8.44 (4.02–17.70)‡
Interleukin-1α 7.26 (3.31–15.95)‡ 8.20 (3.58–18.82)‡
Interleukin-1β 7.16 (3.64–14.09)‡ 7.19 (3.47–14.94)‡
Interleukin-6 5.23 (2.63–10.40)‡ 5.01 (2.43–10.32)‡
Interleukin-8 3.80 (2.02–7.16)‡ 3.73 (1.90–7.32)‡
aAdjusted for age, education, scores on Mini-Mental State Examination and World Health
Organization Disability Assessment Scale II, APOE and physical activity.
*p-value < 0.05; †p-value < 0.01; ‡p-value < 0.001.
Bold character denotes statistical significance after Bonferroni correction.
Data are displayed as odds ratios (95% confidence intervals).
Sums of Higher Baseline Cytokine Levels
and Increases in Cytokine Levels by
Dementia Incidence
Figure 2 shows the combined effects of baseline and follow-up
cytokine levels on dementia incidence. Incident dementia was
associated with increases in the number of changes to higher
cytokine levels during follow-up in unadjusted analyses (χ2 =
50.91; p-value < 0.001). However, no association was found
between the incidence of dementia and increases in the summed
number of higher cytokine levels at baseline (χ2 = 0.604; p
= 0.438). After adjusting for older age, lower education, lower
MMSE score, higher WHODAS II score, lower physical activity,
and presence of the APOE e4 allele, the incidence of dementia
increased significantly with increases in the summed number of
changes to higher cytokine levels at follow-up. No association was
found between incident dementia and increases in the summed
number of higher cytokine levels at baseline.
DISCUSSION
The principal findings of this study were that the incidence
of dementia was significantly associated with increases in
all five serum cytokines, considered as both continuous and
dichotomized variables, at follow-up, and the strength of these
associations remained significant after applying the Bonferroni
correction and relevant adjustments. The analysis of the
combined effects of the five cytokines showed independent
associations between increases in the summed number of higher
cytokine levels between baseline and follow-up before and after
adjustment. The incidence of dementia was only predicted by
higher IL-8 levels at baseline, but this association was no longer
significant in amultivariate analysis after applying the Bonferroni
correction.
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FIGURE 2 | Associations of incident dementia with number of cytokine levels categorize as high at baseline or as showing more pronounced increase over the
follow-up period. Odds ratios (95% confidence intervals) for the association between incident depression and increased summed number of higher cytokine levels at
baseline was 1.08 (0.88–1.33), p-value = 0.437; and between incident dementia and increased summed number of changed higher cytokine levels was 1.91
(1.55–2.34), p-value < 0.001 after adjustment for sex, cognitive function, disability, physical activity, and presence of the APOE e4 allele.
Inflammation may be an important mechanism underlying
dementia (33, 34); however, it is unclear whether the
inflammatory response is associated with the onset of dementia
or is an outcome of dementia. To understand how inflammatory
cytokines change, and possibly exert negative effects in dementia,
a prospective cohort study with numerous inflammatory markers
is needed. Very few studies have incorporated data frommultiple
time points in a clinical sample (35–37). Among them, only
one study reported no association between AD and longitudinal
inflammation (35), and two studies described an association
between increases in inflammatory markers from baseline to
follow-up and subsequent AD (36, 37). In this study, incident
dementia was significantly associated with increases in cytokine
levels during the study period. Several potential mechanisms
might explain these findings. First, the level of inflammation
may serve as a marker of active pathological processes.
Hyperphosphorylation of the tau protein forming neurofibrillary
tangles and amyloid beta (Aβ) accumulation in plaques are
trademarks of AD progression (38). The abnormal Aβ clearance
process results from the distortion of astrocytes or microglia to a
pro-inflammatory state. This process is represented by elevated
levels of pro-inflammatory cytokines and dysregulation of clear
Aβ, and it leads to Aβ accumulation and worsened immune
activation (39). In this study, 41 of 45 (91.1%) participants
with dementia had AD and vascular dementia. Although the
etiologies of AD and vascular dementia may be different, and
thus lead to different disease outcomes, they may begin as a
similar cascade of cytokine production in response to neuronal
injury (8, 38, 39). Increased cytokine levels were significantly
associated with incident AD but not with vascular dementia.
However, due to the small sample size, there is a possibility of
a type II error in the non-significant associations with vascular
dementia. Second, it is also possible that cytokines increased
due to causes other than dementia during the follow-up period.
For example, normal aging can cause an increase in peripheral
cytokines (33, 40). Our longitudinal observations support this
hypothesis. Five cytokines increased during the follow-up period
in both the dementia and control groups. The term sensitization
is often used to describe induction of an immune response.
Here, the incidence of dementia was associated with an increase
in cytokine levels, but not with the absolute concentrations of
baseline cytokine levels. Therefore, when conditions other than
aging occur that can accelerate inflammation, such as amyloid
plaques and neurofibrillary tangles (9), depression (9), genetic
conditions (41), infections (42), trauma, and vascular events (8),
immune sensitization can occur, which can accelerate cognitive
impairment.
Previous studies of cross-sectional cytokine levels as
predictors of the incidence of dementia have resulted in
heterogeneous findings (35, 43–45). Those studies were limited
by differences in study design, such as participant characteristics.
In our study, baseline IL-8 level was associated with incident
dementia in unadjusted analyses, but was not significant in the
multivariate analysis after applying the Bonferroni correction.
Furthermore, the impacts of cytokines have been revealed
to be synergistic and, given the inconsistent outcome of a
single cytokine level, the combined effect of multiple cytokines
represents a more practical approach (21, 46). No associations
were detected when high cytokine levels were summed. Together,
these data do not support the hypothesis that cytokines result in
dementia-related dysfunction but, instead, suggest that cytokine
levels are elevated by dementia-related processes.
This study has several strengths. Cytokine levels were assessed
serially, which could help to clarify causal relationships. In
addition, the follow-up rate was reasonable and a number of
potential covariates were considered in the analyses. This study
also has several limitations. First, due to limited resources,
we only measured five cytokines, and other important anti-
inflammatory (e.g., IL-4 and IL-10) and pro-inflammatory
(e.g., IL-13 and IL-18) cytokines were not evaluated (47).
It is important to determine the exact function of various
cytokines and disease progression. Overproduction of several
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cytokines could result in damage to neurons, and these cytokines
may play a role in the progression of dementia, but their
protective effects have also been considered (47). Second,
we collected blood samples from the periphery to measure
inflammation in the central nervous system. Several studies have
been conducted using imaging technology, including positron
emission tomography, to measure neuroinflammation directly
in subjects with dementia (48, 49). More studies are required
to demonstrate the relationships between these cytokines and
dementia. Third, due to protein degradation, it is recommended
that blood samples be examined immediately. In this instance,
due to technical difficulties, they were centrifuged at 3,000 rpm
for 10min, and sera were stored at −70◦C until we finished
specimen collection. However, most studies follow this procedure
(20, 50). Fourth, the small set of covariate-adjusted analyses
leaves the possibility of confounding bias. For example, we
adjusted for age, education, MMSE, WHODAS, and physical
activity but not for alcohol, smoking, or body mass index, which
did affect the associations between cytokine levels and dementia,
although these factors were not significantly associated with
incident dementia at the follow-up (Supplementary Table 1).
In particular, we could not provide an accurate diagnosis for
smoking and alcohol use. Varying the cutoff points may lead
to a different interpretation of the results of a trial. Thus,
our adjustment might have been suboptimal. Fifth, conclusions
regarding dementia that fully reflect the complex disease status
are improbable, as stated above. In this study, due to a
limitation in the study design, the probability that increases in
cytokines may arise transiently, as in acute infectious disease, or
continuously because of chronic inflammatory disease, may have
influenced the heterogeneity, and both diseasesmay contribute to
incident dementia. In addition, it was difficult to diagnose mixed
dementia due to a lack of brain imaging data. However, this
limitation is common in most epidemiological studies. Finally,
because this study did not specify the timing of the dementia
diagnosis, it was not possible to state clearly that dementia
preceded inflammation. Furthermore, only 2 years of follow-
up visits were carried out. Because dementia progresses over
decades, having a longer follow-up is crucial to identifying the
developmental trajectory of the disease. Additional follow-up
studies will be needed to address these limitations.
Our findings suggest that incident dementia may lead
changes in serum cytokine levels and inflammation, rather than
resulting from elevated pro-inflammatory cytokines. It has been
reported that patients with dementia, particularly those at more
advanced stages, are at a higher risk for developing stroke and
depression (51, 52), which could, theoretically, be mediated
by inflammation. As mentioned above, our findings must be
replicated in future studies with more cytokines. Furthermore,
interactions between cytokine levels and genes need further
assessment, as there is sufficient evidence that the transcriptional
activity of specific polymorphisms influences cytokine
production (53).
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